
A study on ROS1 fusions in non-small cell lung cancer (NSCLC) patients in China has revealed new insights. The study analyzed 135 ROS1 fusions in 134 patients using next-gen sequencing. They found common fusions in introns 31-33 and uncommon ones in 34-35, with previously unknown breakpoints in intron 28. Fusion partners correlated with ROS1 breakpoints. Inconsistencies between DNA and RNA-based sequencing were attributed to alternative splicing. These findings enhance our understanding of ROS1 fusions, impacting panel design and treatment strategies for NSCLC patients with ROS1 rearrangements. This study sheds light on a crucial therapeutic target in NSCLC.
Like
Save
Share